pf-05212377
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00948662)
Timeline
Indications
Mechanism of action
- Serotonin 6 (5-HT6) receptorANTAGONIST
HTR6 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1- Mol. weight
- 356.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545344 ↗
- ChEMBLCHEMBL3329435 ↗
Also known as
- pf-05212377
- pf-05212377
- pf-5212377
- sam-760
- sam-760
- wye-103760
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02005991 | Phase 1 | Nov 1, 2013 | Pfizer |
| NCT01712074 | Phase 2 | Nov 1, 2012 | Pfizer |
| NCT01213355 | Phase 1 | Apr 1, 2011 | Pfizer |
| NCT01258751 | Phase 1 | Dec 1, 2010 | Pfizer, Yale University |
| NCT01159496 | Phase 1 | Jul 1, 2010 | Pfizer |
| NCT00948662 | Phase 1 | Sep 1, 2009 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 2 | 2009 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1